Free Trial

Vaccinex (VCNX) Stock Price, News & Analysis

-0.36 (-4.94%)
(As of 07/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
120,421 shs
Average Volume
21,807 shs
Market Capitalization
$10.96 million
P/E Ratio
Dividend Yield
Price Target

Vaccinex MarketRank™ Stock Analysis

Analyst Rating
Short Interest
2.19% of Float Sold Short
Dividend Strength
News Sentiment
0.21mentions of Vaccinex in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$4,737 Bought Last Quarter
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.57 out of 5 stars

Medical Sector

675th out of 901 stocks

Pharmaceutical Preparations Industry

320th out of 426 stocks

VCNX stock logo

About Vaccinex Stock (NASDAQ:VCNX)

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

VCNX Stock Price History

VCNX Stock News Headlines

Forecaster with 99.8% Accuracy Makes Shocking Prediction
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Vaccinex faces Nasdaq compliance challenge
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
Vaccinex Inc VCNX
See More Headlines
Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($2.59) per share


Free Float
Market Cap
$10.81 million
No Data
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Maurice Zauderer Ph.D. (Age 77)
    Co-Founder, CEO, President & Director
    Comp: $411.7k
  • Dr. Elizabeth E. Evans Ph.D. (Age 51)
    COO and Senior VP of Discovery & Translational Medicine
    Comp: $291.57k
  • Dr. Ernest S. Smith Ph.D. (Age 52)
    Senior VP of Research & Chief Scientific Officer
    Comp: $297.25k
  • Ms. Jill Sanchez CPA (Age 52)
    Chief Financial Officer
  • Dr. John E. Leonard Ph.D. (Age 77)
    Senior Vice President of Development

VCNX Stock Analysis - Frequently Asked Questions

How have VCNX shares performed this year?

Vaccinex's stock was trading at $9.3072 at the beginning of the year. Since then, VCNX stock has decreased by 25.6% and is now trading at $6.9206.
View the best growth stocks for 2024 here

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) released its earnings results on Wednesday, May, 15th. The company reported ($2.94) EPS for the quarter. The company earned $0.10 million during the quarter.

When did Vaccinex's stock split?

Vaccinex's stock reverse split on Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Vaccinex IPO?

Vaccinex (VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL) and Pfizer (PFE).

This page (NASDAQ:VCNX) was last updated on 7/25/2024 by Staff

From Our Partners